Collegium Pharmaceutical (COLL) Interest Expenses (2014 - 2026)

Collegium Pharmaceutical's Interest Expenses history runs 13 years deep, the most recent figure standing at $91.1 million for Q1 2026.

• On a quarterly basis, Interest Expenses changed 0.0% year-over-year to $91.1 million in Q1 2026; TTM through Mar 2026 was $91.1 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $110.9 million, up 49.86% from the prior year.
• Interest Expenses rose to $91.1 million in Q1 2026 per COLL's latest filing, from $19.3 million in the prior quarter.
• Across five years, Interest Expenses topped out at $91.1 million in Q3 2024 and bottomed at $15.6 million in Q2 2024.
• The 5-year median for Interest Expenses is $22.7 million (2024), against an average of $52.1 million.
• Across the five-year window, Interest Expenses soared 1381.45% in 2022 and sank 74.99% in 2023, its largest moves.
• Year by year, Interest Expenses stood at $20.6 million in 2022, then retreated by 6.29% to $19.3 million in 2023, then advanced by 17.49% to $22.7 million in 2024, then declined by 14.84% to $19.3 million in 2025, then jumped by 372.29% to $91.1 million in 2026.
• Per Business Quant, the three latest COLL Interest Expenses figures stand at $91.1 million (Q1 2026), $19.3 million (Q4 2025), and $91.1 million (Q3 2025).